Clinical Obesity Now Dominates Bariatric Surgery Candidacy Across Four Countries
A new JAMA Network Open study places a familiar surgical population into a different clinical frame. Among adults undergoing primary metabolic bariatric surgery, clinical obesity accounted for nearly three-quarters of cases, suggesting that the majority of patients arriving for surgery already carried excess adiposity with established organ dysfunction rather than preserved physiologic reserve.
The study matters because bariatric programs have long relied on body mass index as the main gatekeeper for treatment access. The newer framework proposed by the Lancet Diabetes and Endocrinology Commission separates clinical obesity from preclinical obesity, using the presence of obesity-related organ dysfunction to define disease severity more precisely than BMI alone. In practical terms, that shift asks surgeons and obesity specialists to look beyond weight and ask what the adipose burden has already done to the body.
Across 4 high-volume tertiary centers in the UK, Spain, France, and Brazil, investigators audited adults who underwent primary laparoscopic gastric bypass or sleeve gastrectomy between January 1, 2014, and December 31, 2025. Revisional procedures and patients who had multiple bariatric operations within the same year were excluded. The cohort included 2316 patients in total, giving the analysis enough breadth to examine how this new obesity taxonomy maps onto real-world surgical practice.
The central finding was blunt. Of the 2316 patients, 1709, or 73.8%, met criteria for clinical obesity, while 607, or 26.2%, were classified as having preclinical obesity. Clinical obesity was the dominant category at every site, ranging from 62.7% in Brazil to 79.3% in the UK. In a field that often discusses obesity as a threshold problem, the data show that most surgical candidates have already crossed into end-organ disease territory before the operation even begins.
One sentence captures the clinical reality: bariatric surgery is increasingly being offered to patients whose obesity is already biologically complicated.
The demographic pattern also ran in a consistent direction. Patients with clinical obesity were older than those with preclinical obesity across cohorts, with mean ages ranging from 45.6 to 48.9 years in the clinical group versus 34.7 to 40.0 years in the preclinical group. Women made up the majority of both groups, but they were proportionally more common in the preclinical cohort, where 486 of 607 patients were women, or 80.1%, compared with 1149 of 1709 patients, or 67.2%, in the clinical cohort. Those differences are clinically intuitive: as adiposity persists over time, the burden of cardiometabolic, respiratory, musculoskeletal, and other organ-level consequences accumulates, and the surgical population begins to skew toward older patients with established disease.
BMI, meanwhile, still told part of the story, but not all of it. Mean BMI ranged from 40.2 in the Brazilian preclinical cohort to 48.5 in the UK preclinical cohort. The study also reports BMI levels and BMI category distributions, though the excerpted data do not extend to the full distribution details. Even with that limitation, the broad message is clear: BMI alone does not distinguish the patient with excess weight from the patient whose excess weight has already produced measurable dysfunction.
The operational value of the study lies in its attempt to translate a conceptual obesity framework into the surgical setting. Metabolic bariatric surgery remains the most effective treatment for severe obesity, yet access decisions have often rested on a numerical cutoff rather than the biologic injury caused by adiposity. A patient with preserved organ function and another with obesity-related organ dysfunction may share the same BMI, but their perioperative risk profile, cardiometabolic reserve, and long-term disease trajectory are not necessarily equivalent. The new classification is designed to capture that difference, and this multicenter audit suggests the distinction is not academic. It identifies a large majority of surgical candidates as already living with clinical disease.
The study design also strengthens its relevance to practice. Data were collected from high-volume tertiary centers in 4 countries, offering a multinational snapshot of current bariatric referral patterns. Comparative analyses between clinical and preclinical obesity were performed within each cohort, and no direct statistical comparisons were made between centers because patient-level data were not shared across sites. That approach limits cross-country inference, but it preserves the integrity of the cohort-level analysis and avoids overstating differences that may reflect local referral pathways, case mix, or coding practices rather than biology.
The investigators also planned secondary evaluations of organ dysfunction patterns, ASA classification, Charlson Comorbidity Index, estimated 10-year cardiovascular risk using the Framingham risk score, and 30-day major postoperative complications defined as Clavien-Dindo grade 3 or higher. Those outcomes are exactly the right ones for this discussion, because they connect the obesity taxonomy to what surgeons and anesthesiologists care about at the bedside: who is sicker, who carries more operative risk, and who is likely to benefit from intervention before irreversible damage advances further. The excerpt provided does not include the full comparative results for those endpoints, so any deeper numerical claims would overstep the available data.
Even without the missing endpoint detail, the clinical implication is substantial. If most bariatric candidates already fall into the clinical obesity category, then surgical programs, insurers, and obesity clinics may need to recalibrate how they think about eligibility, prioritization, and timing of intervention. A BMI threshold can identify excess size, but it cannot tell whether the heart, liver, pancreas, or other organs have begun to fail under the strain of adiposity. The new framework places organ dysfunction at the center of decision-making, which is where surgical triage arguably belongs.
The study leaves one practical tension unresolved: a classification that better reflects biology still requires consistent bedside assessment. If clinical obesity is to guide surgical pathways, teams will need standardized ways to document obesity-related organ dysfunction across health systems and continents. Without that consistency, the category could become harder to apply than the BMI cutoffs it is meant to improve.